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A sequence of three programs is described for efficient design and analysis of radio- 
immunoassays. The first program designs the assay; the second program analyzes all 
available data according to the organizational base provided by the first program: 
and the third program summarizes the results of several assays in either tabular or 
graphical form. The analysis program uses a logit response-log dose transformation to 
obtain a linear inhibition curve for all preparations assayed at multiple levels. The curves 
are subjected to a weighted, least squares, regression analysis. All curves are tested for 
linearity and parallelism with the curve chosen as standard, and a weighted mean potency 
estimate with error limits is computed for all preparations run at single or multiple dose 
levels with any degree of replication. 
The increasing use of computer technology for handling large amounts of radio- 
immunoassay data has been brought about by two considerations. First, the 
calculation process is a time-consuming chore. The burden of making the necessary 
calculations involved in sophisticated statistical tests for estimation of error or 
evaluation of curves virtually precludes the use of any manual system. The second 
evaluation of curves virtually precludes the use of any hand system. The second 
consideration is the need for convenient processing and summary of the additional 
data which may be produced as more efficient methods of calculation become 
available. The set of three programs presented here provides not only a reasonably 
sophisticated calculation structure, but also a total data processing system which 
facilitates the steps from assay planning to data summary analysis. It is designed 
for use in double antibody radioimmunoassays, but would be valid for other binding 
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assays employing radioisotopically labeled ligand in which the radioactivity of the 
bound fraction is counted, regardless of the isotope employed. 
This system consists of three procedures: protocol of assay, calculation of results, 
and summary of data (see Fig. 1). The protocol program designs the assay, describes 
FIG. 1. Flow diagram of the total system; figure illustrates the relation between the inputs, outputs 
and programs. 
all tubes in detail, determines the position of each tube in the assay, and serves as 
the organizational base upon which the other two programs are constructed. The 
calculation program analyzes the standards and unknowns, producing error 
estimates, a variety of statistical validity checks, and optional data summary cards. 
When appropriate data summary cards have been collected from one or more 
assays, they are used as input to the summary program. This third program produces 
either tabular or graphical summary results, or both, on single or multiple obser- 
vations which are in single or multiple treatment groups. 
I. The Protocol 
DESCRIPTION OF PROGRAMS 
By means of the assay planning sheets, the investigator indicates which standard 
and unknowns are to be run in the assay. This step has not proven as cumbersome 
as originally feared. Cards are keypunched from the assay planning sheets (see 
Fig. 2, listing of protocol deck). Parameters to be entered for each unknown include 
sample identification (up to 24 characters), sample volume, number of replications 
at each dose level, number of dose levels, dilution factor between dose levels if 
more than one are employed, and concentration of unknown. 
Several considerations reduce the effort necessary to produce this deck of cards. 
For example, one protocol card can specify assay details for many tubes. If an 
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unknown is to be run in duplicate at ten dose levels, twenty tubes will be protocolled 
by a single protocol card. Further, several defaults have been built into the program. 
In many cases, only the sample identification must be keypunched for an unknown, 
and the remainder of the card may be left blank. The program then uses the specifi- 
cations set for the previous protocol card to describe the new sample. The protocol 
cards serve as input data to the protocol program (PROTOC), which produces 
assay protocol sheets (see Fig. 3, output from protocol program). 
The assay protocol sheets contain all information necessary to set up the assay. 
The heading area describes parameters pertinent to the assay as a whole. Subse- 
quently, each tube in the assay is described in detail. Identification and concentration 
CARD TYPE INPUT -- 
Assay Number D136-30 
Type of Assay OFSHHFSHHFSH 
Purpose of Assay DETERMINE FSH CONCENTRATION IN PREPARATIONS 
Oiluent PBS-l%E.W. 
Anti-serum ANTI-OFSH 1:1800 
Excess Anti-body NONE 
Labled Prep 8144 1327 
Anti-RGG #9 1:12 
Incubation 24+24+72 
Standard STNO 856 200.3. 9. .5 80. MI 
Unknown 8518 100.2. 5. 0.1 ML 
II B519 200. 1.0 UG 
II R1429-2 8564 2. .l 7.7 II R1429-3 8565 15.2 
FIG. 2. Input to protocol program; card type explains the information on each line. The input 
is in formatted card image form, as it would be submitted to the computer. 
of the sample, its tube number in the assay, and the amount of sample and buffer 
solution are indicated. Tubes described by the protocol program include the 
standard and unknowns protocolled by the investigator, as well as tubes common to 
all assays. Common tubes which are automatically protocolled include total count 
tubes (containing only labeled ligand), background tubes (containing nonimmune 
serum in place of antiserum) and buffer control tubes (containing antiserum and 
buffer, but no competing unlabeled ligand). 
The order of the tubes in the assay is determined by the program. A standard 
curve is placed at the beginning and end of the assay-if the standard is to be run 
in triplicate, the third one goes in the center-which serves as a check on the assay’s 
continuity. With this consistent, unambiguous sheet in hand, the technician is ready 
to set up the assay. The cost of running the program for a 300 tube assay at the 
University of Michigan Computing Center is roughly 75e. 
II. The Calculations 
Inputs to the calculation program (RIANALS) are three. First is the protocol data 
deck which was previously used as input to the protocol program. RIANALS must 
have identification for all data produced by the radioisotope counter. The protocol 
deck is the medium by which this is accomplished. 




















#9 1:12 ._.  ~. 
INCUBATION 24+24+7 
TUBE # CONC LABEL 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
1 
2 E 
/ML TOTAL COUNTS 
3 0:o 
/ML TOTAL COUNTS 
/ML TOTAL COUNTS 
4 0.0 /ML NRS(BACKGROUND) 
5 0.0 /ML NRS(BACKGROUND) 
6 0.0 /ML NRS(BACKGROUND) 
7 0.0 /ML BUFFER CONTROL 
8 0.0 /ML BUFFER CONTROL 
9 0.0 /ML BUFFER CONTROL 
10 BO.OOOMI/ML 856 
11 BO.DOOMI/ML 856 
12 BO.OOOMI/ML 856 
13 BO.OOOMI/ML 856 
14 BO.OOOMI/ML 856 
15 BO.OOOMI/ML 856 
16 BO.OOOMI/ML B56 
17 BO.OOOMI/ML 856 
18 BO.OOOMI/ML 856 
19 O.lOOML/ML 8518 
20 O.lOOML/ML 8518 
21 O.lOOML/ML 8518 
22 O.lOOML/ML B518 
23 O.lOOML/ML 8518 
24 O.lOOML/ML 8518 










26 O.lOOML/ML 8518 
D.lOOML/ML B518 
;; O.lOOML/ML 8518 
29 l.OOOUG/ML B519 29 200.0 300.0 
30 l.DOOUG/ML 8519 30 200.0 300.0 
69 BO.OOOMI/ML 856 -STD 69 1.6 498.8 
70 BO.OOOMI/ML 856 -STD 70 0.8 499.2 
. . . 
IN PREPARATIONS 
SAMPLE BUFFER 
TUBE # UL/TUBE UL/TUBE 






4 0.0 500.0 
5 0.0 500.0 





























FIG. 3. Output from protocol program: the heading information is echoed from input. Selected 
output lines are shown, including total count and background tubes at the front of the assay, and 
a standard curve at the beginning and end. 
The second source of input is a set of modification cards, all optional describing 
changes to the assay as protocolled which the investigator may wish to make because 
of whim or circumstance. These options include the ability to : 
1. Describe tubes which were added to and counted at the end of the assay, in 
addition to those originally protocolled. 
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2. Delete all reference in the output to any unknown sample which was not 
set up or counted properly, e.g., one which was dropped or for which 
insufficient sample was available. While a single standard tube may not be 
eliminated, any of the multiple standard curves may be ignored. 
3. Change the concentration or sample volume of any unknown which was not 
run with the protocolled value for either or both of these parameters. 
4. Indicate a delay in the counting procedure. RIANALS is designed to correct 
raw counts for half-life decay (the user supplies the decay factor for the 
isotope to be used) from the time the assay begins counting. Exercising this 
option thus allows for any discontinuity in the counting process. 
5. Use any other preparation run in duplicate at multiple dose levels as the 
standard in place of the original standard. This is quite convenient for 
measuring the relative potency and parallelism of several preparations 
against each other. 
The third input is a deck containing the results produced by the counting device. 
Each card contains a tube number, counting time, and number of counts. Any 
combination of preset time or preset counts may be used to obtain any desired 
counting error within the desired period of time. These cards may be produced 
automatically by any one of several available devices connecting counter and 
keypunch. The order of the cards in the deck corresponds to the tube sequence and 
is exactly the same as indicated on the protocol sheet. 
Calculations and output-RIANALS (see Fig. 4, flow sheet for RIANALS). 
RIANALS first reads the protocol deck and internally reproduces the protocol, so 
that it can identify each count card as that deck is read in. Modifications to the 
protocol, if any, are made according to the modification cards. The count cards are 
then read in as indicated by the modified protocol. 
Background is calculated and all counts are converted to counts per minute 
corrected for background and isotopic decay. The default decay correction is based 
on the elapsed time of the assay and the half-life of i311 The elapsed time is the sum . 
of the counting time plus the time required to change samples. The sample changing 
time employed is 25 seconds, but the program could be easily modified to use a 
different figure. If an isotope other than 13’1 is counted, the appropriate half-life may 
be substituted by means of a protocol option card. 
Having completed the above calculations, RIANALS checks the IGNORE option. 
If the option to ignore one standard curve has been exercised, the curve is expunged, 
as are individual unknown tubes, if so specified. Total count and background tubes 
areanalyzedandtheresultsprintedout(seeFig. 5, thebeginningofRIANAL5output). 
Next, the buffer control tubes are analyzed. These tubes serve as the 100 % point, 
the point against which all other tubes are measured for calculation ofpercent bound. 
Three buffer control tubes are run with each standard curve, resulting in six or nine 
of these tubes, depending on the number of standard curves. 
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FIG. 4. Flow chart of RIANALS: the internal logic of the calculation program is shown sche- 
matically at a low level of detail. 
A mean counts per minute value is calculated for each set of triplicate buffer 
controls, and the individual values converted to a percent of their respective means. 
The variance of these percent terms, of each set for triplicates, is calculated and 
compared against the rejection criterion (see Error Analysis below). Following the 
rejection of replicates, if any, an overall mean count per minute value is calculated. 
This serves as the 100 % point. The variances are stored for later inclusion with those 
of all other replicates, and all buffer control information is printed. 






















STND 856 -STD 80.00 MI/ML 
TOTAL COUNTS PER MINUTE 17864. CPM %SD = .072 
COR CPM 17863. 17864. 17865. 
AVERAGE BACKGROUND 319. CPM % OF TOTAL 1.8 
COR CPM 305. 284. 368. 
BUFFER CONTROL 5457. CPM % OF TOTAL 30.5 % SD 2.17 
COR CPM 5274. 5370. 5469. V. RATIO 0.0332 
COR CPM 5576. 5475. 5577. V. RATIO 0.0114 
COR CPM 5429. 5507. 6434. V. RATIO 0.0223 
VARIANCE RATIOS FOR ASSAY REPLICATES 
0.0 :::016 :*:017 0.0001 0 0010 
0'0025 
0.0013 0 0014 
0.0015 0.0025 0 0036 0'0041 
0.0053 0.0063 0:0067 0.0068 0:0076 0:0078 0:0089 
0.0122 0.0126 0.0144 0.0161 0.0175 0.0184 0.0204 
0.0243 0.0246 0.0267 0.0294 0.0295 0.0318 0.0328 
0.0348 0.0358 0.0361 0.0370 0.0397 0.0408 0.0415 
0.0445 0.0473 0.0567 0.0580 0.0581 0.0797 0.0822 
0.1091 0.1135 0.1361 0.1509 2.3000 3.3350 7.6437 
53.7689 
MEDIAN VARIANCE RATIO 0.0204 
VARIANCE RATIO OF BUF. CON. 0.0223 
FOG. 5. Output from RIANALS: first page of output from the calculation program echoes the 
heading information from the protocol, details the total counts, background and buffer control 
tubes and establishes means for each. The variance ratio for each set of replicates in the assay is 
printed. 
Error analysis for entire assay. A linear relationship between the variance of a 
replicate set .Y*) and the percent bound (p) at which this set is read over most of the 
radioimmunoassay inhibition curve has been previously established (I, 2). RIANALS 
determines this relationship for each assay as it is calculated. Once computed, the 
relationship permits determination of a theoretical variance for each individual 
tube, which is later used as a weighting factor in the calculation of a mean potency 
estimate. 
Since p vs. s2 is approximately linear, the “variance ratio” (r = s2/p) is essentially 
constant at all points. If s2 were normally distributed, the slope (r) of the linep vs. s2 
would be the mean of all variance ratios in the assay. Since .r2 is not normally 
distributed, we have chosen the median variance ratio R = median r. Experience has 
provided statistical support for this technique; from over approximately 100 assays 
tested, the median variance ratio predicted by the entire assay has proved to be not 
significantly different from the variance ration of the buffer control tubes (the 100% 
point on the curve). 
Replicate samples are rejected when the variance ratio exceeds 1.12. This constant 
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would be exceeded if two tubes containing buffer gave responses equal to or further 
apart than 92.5 and 107.5%. This rejection criterion is without theoretical basis, 
representing the level of disagreement between estimates which is unacceptable to 
our laboratory. In over 47 assays, tested in a variety of assay systems, 117 of 3935 
replicate sets were rejected-roughly a 3 ‘4 rejection rate. 
Analysis of standard curve. An equation to describe the standard curve is obtained 
according to the methods of Rodbard (2) and Finney (3). An initial estimate of 
slope and intercept of the logitp vs. log potency standard curve is made by unweighted 
linear regression on those points between 10 % and 90 %. Modification of the initial 
estimate is accomplished by calculating a new series of responses-the working logit. 
The weight given each point for the weighted least-squares regression is the reciprocal 
of the variance of the logit of (2) p: 
var (P) variance logit (p) = -___ 
p*(loo-p)’ 
The variance ofp is calculated from the error relationship established earlier. Thus, 
var(p) =p*R 
where R is the median variance ratio. Substituting 
1 wt = -- _ = pJOW2 
variance logit (p) ~7. 
The process of weighting and calculating a new slope using all points between 0 and 
100% is repeated ten times. Experience has shown that differences between 
subsequent estimations of the slope to the third decimal place disappear after three 
or four such iterations. 
The final estimation of the curve is then checked for linearity by determining if the 
scatter of mean values about the curve is significantly different from that predicted 
from within group variation. This check, and further statistical calculations noted 
for standard and unknowns, are from Finney (3) and Bliss (4). Following the linearity 
check, a table ofresultsforthestandard curve is printed (see Fig. 6, p. 2 of RIANALS 
results). The table includes the doses, responses, means of the responses, and the 
theoretical response of each dose read off the final estimate of the standard curve. 
It should be noted that the “linearity” check does not test for systematic curvature 
and thus this check often indicates “non-linearity” when only random departure 
from linearity is present. If the curve is linear, the data are suitable for logit analysis. 
In addition, the investigator may check the fit by examining the table provided 
(Fig. 6). The difference between the mean response at each dose level and the 
theoretical value read from the logit fit should be small and random. In most cases, 
these differences are less than, or roughly the same as, the range of the responses 
which make up each mean response. 
Calculations of unknowns. Each unknown is treated in the same manner as the 
standard curve. If the unknown is run at a single dose level, the first estimate of the 
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OFSHHFSHHFSH D136-30 04-02-71 PAGE 2 
STANDARD DOSE-RESPONSE CURVE 
DOSE CURVE1 CURVE2 CURVE 3 RANGE MEAN LOGIT 
16.0000 MI 8.9% 10.2% 8.7% 1.5 9.3% 9.2% 
8.0000 MI 20.0% 22.0% 18.2% 3.8 20.0% 21.3% 
4.0000 MI 38.7% 44.7% 49.9% 11.2 44.4% 41.8% 
2.0000 MI 66.2% 61.5% 65.7% 4.7 64.5% 65.6% 
1.0000 MI 81.3% 80.5% 82.1% 1.6 81.3% 83.5% 
500.0000 UI 90.7% 97.3% 97.3% 6.6 95.1% 93.1% 
250.0000 UI 94.1% 98.9% 95.0% 4.8 96.0% 97.3% 
125.0000 UI 99.1% 97.0% 98.6% 2.0 98.2% 99.0% 
62.5000 UI 98.7% 96.1% 100.3% 4.2 98.4% 99.6% 
EST SLOPE .S.E. SLOPE 
lb -3.243 117 0.0 97 









SLOPE OF STANDARD CURVE -3.24 
INTERCEPT OF STANDARD CURVE 1.62 
RESIDUAL VARIANCE 0.0340 
LAMBDA -0.0105 
OBSERVED F OF LINEARITY 1.1374 
SIGNIFICANCE LEVEL 0.3839 
STANOARO CURVE IS LINEAR 
DOSES ON THEORETICAL CURVE 
95.0% 390.3921 UI/TUBE 
90.0% 663.6316 UI/TUBE 
85.0% 921.7031 UI/TUBE 
80.0% 1.1803 MI/TUBE 
70.0% 1.7307 MI/TUBE 
50.0% 3.1587 MI/TUBE 
30.0% 5.7650 MI/TUBE 
20.0% 8.4530 MI/TUBE 
10.0% 15.0344 MI/TUBE 
100%-l S.E. OF B.C. 
(LIMIT OF DETECTION) 
74.0114 UI (99.5%) 
100%-l S.D. OF ASSAY 247.8509 UI (97.3%) 
(DERIVED FROM MED. VAR. RATIO) 
lOO%-2 S.D. OF B.C. 274.7368 UI (97.0%) 
FIG. 6. Output from RTANALS: second page of output is a description of the standard curve. 
“RANGE” is difference between high and low values at a dose level. “MEAN” is the mean of values 
at a dose level. “LOGIT” is the value obtained by reading dose off theoretical standard curve. 
“DIFF” is difference between mean and logit. “EST” is n-th estimate of slope in the iterations 
to establish the standard curve. “B.C.” stands for “buffer control tubes”. Three different methods 
for determining assay “sensitivity” are provided. 
curve produces a mean log potency and a slope of zero. No further estimates of 
the slope are attempted and the anti-log of the mean log potency is the mean potency 
estimate. Since a curve does not exist, none of the statistics associated with a curve 
is calculated or printed. 
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OFSHHFSFHFSH 0136-30 04-02-71 PAGE 3 
8518 
19 lOO.OUL/T 1157.CPM 21.% 8.031MI 803.12 MI/ML 
20 lOO.OUL/T 1217.CPM 22.% 7.851MI 785.14 MI/ML 
21 50.0'JL/T 2396.CPM 44.2 3.787MI 757.57 MI/ML 
22 SO.OUL/T 224B.CPM 41.% 4.069MI 813.83 MI/ML 
23 25.OUL/T 3536.CPM 65.2 2.064MI 825.46 MI/ML 
24 25.OUL/T 3400.CPM 62.% 2.201MI 880.45 MI/ML 
25 12.5UL/T 4186.CPM 77.% 1.326MI 1.06 I/ML 
26 12.5UL/T 4387.CPM 80.% 1.169MI 935.21 MI/ML 
27 6.2UL/T 4966.CPM 91.% 0.609MI 973.60 MI/ML 
28 6.2UL/T 4879.CPM 89.% 0.704MI 1.13 I/ML 
VAR SLP LAMBDA OBS F LIN SIG LIN CRIT F OBS F PARALLEL 
UNKN 0.0262 -2.950 -0.009 2.240 0.202 YES 4.13 3.40 YES 
COMB 0.0006 -3.153 -0.008 2.022 0.063 YES 
8518 O.lOOML/ML 815.54(787.12-845.07)MI/ML N=lO 
B519 
29 LOO.OUL/T 1643.CPM 30.% 5.67DMI 28.35 MI/UG 
30 EOO.OUL/T 
lOO.OULjT 
1817.CPM 33.% 5.188MI 25.94 MI/UG 
31 3078.CPM 56.% 2.691MI 26.91 MIilJG 
32 lOO.OUL/T 3085.CPM 56.% 2.675MI 26.75 MI/UG 
33 50.0UL/T 3934.CPM 72.% 1.642MI 32.83 MI/UG 
34 50.0UL/T 4027.CPM 74.% 1.507MI 30.14 MI/UG 
35 25.OUL/T 
36 25.OUL;T 
4786.CPM 88.% 0.762MI 30.46 MI/UG 
4546.CPM 83.% 1.035MI 41.41 MIiUG 
37 12.5UL/T 4911.CPM 90.% 0.667MI 53.35 MI;UG 
38 12.5UL/T 4906.CPM 90.% 0.678MI 54.22 MI/UG 
VAR SLP LAMBDA OBS F LIN SIG LIN CRIT F OBS F PARALLEL 
UNKN 0.0406 -2.789 -0.015 3.066 0.130 YES 4.13 5.91 NO 
COMB 0.0007 -3.131 -0.008 2.759 0.014 NO 
8519 l.OOOUG/ML 27.85( 26.80- 28.93)MI/UG N=lO 
R1429-2 B564 
FIG. 7. Output from RIANALS: third and successive pages show calculation of unknowns. 
Printed for each tube are volume of unknown, resulting counts per minute, percent of buffer con- 
trol, amount of unknown per tube, and concentration of unknown in sample. When multiple dose 
levels are run, printed for both the unknown and combined curves are the residual variance, slope, 
lambda, F test for linearity, the probability value for the F test, and whether it is significant at the 
.05 level. For the unknown curve alone, an F test is used to check parallelism with the standard. 
Finally, the name and concentration of the unknown, the mean and one standard error confidence 
limits, and the number of individual values used in the calculation of the mean are printed. 
“COMB” lists values for the combined curve. A test for homogeneity of variance for the standard 
and unknown has not been included. 
For an unknown run at multiple dose levels, standard parallel line bioassay-type 
statistics are employed (3, 4). After the linearity of the unknown curve and the 
significance of its slope are established, the curve is tested against the standard for 
parallelism. A mean potency estimate is then calculated using the slope of the 
combined curve of the standard and unknown. If the curves are not parallel, the 
mean potency is still calculated, but the investigator must use his knowledge of his 
own assay system in deciding whether such a result is meaningful. 
Printout for each unknown sample includes tube number, sample volume, 
corrected counts per minute, percent bound, amount of measured ligand in the tube, 
and concentration of measured hormone in the unknown (see Fig. ‘7, p. 3 of 
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RIANALS output). A mean potency estimate with estimates of error is printed for 
each unknown. These error estimates represent one standard error on either side 
of the mean. Conversion of log units to antilogs results in unequal intervals between 
the mean and the upper and lower values. If the unknown was run at multiple dose 
levels, a table of statistics is printed which pertains to both the resulting and unknown 
combined curves. Values include the residual variance, slope, lambda, F-tests for 
linearity and parallelism, and additional comment if the slope is not significant. 
If requested, a summary card is punched specifying essentially the same infor- 
mation available on the printed line containing the mean potency estimate. The 
exercise of this option produces cards for input to the summary program. The cost 
of running RIANALS with a 300 tube assay at the University of Michigan Com- 
puting Center is about $3.00. 
III. The Summary 
Machine specificity. Several routines in the summary program (RSUM)-par- 
titularly those used to produce the plots-are specific to the University of Michigan 
computer facility. Substantial reprogramming would be required to make RSUM 
run at any other facility. Consequently, discussion of RSUM will be more brief and 
theoretical to facilitate communication of the principles underlying the program. 
Overview. The summary program (RSUM) is designed to summarize observations 
made over time. The relation of values to each other through a defined time sequence 
is the assumed basis of the experiment to be summarized. Measurement of hormones 
in menstrual cycles is an example of the type of problem which the program is 
designed to process. 
The analysis technique employed is to choose a time segment of a defined number 
of days, hours, or minutes, and scan across all the data for a specific number of such 
segments. Segments may contain one or more data values, or indeed, none at all, 
depending on the sequence of observations along the time line. A mean and variance 
are calculated for each segment. These are printed, together with the number of 
values they represent. The same technique is used whether the data scanned represent 
a single individual, multiple individuals combined in one treatment group, or a 
combination of treatment groups. 
Three time points may be defined in the data-the beginning, the end, and a 
variable point of interest between the extremes to be specified by the investigator. 
A peak level for a subject in question would be an example of such a point. The scan 
across the data can originate at any of the three points, permitting data on multiple 
individuals to be combined and synchronized in four different ways. That is, four 
separate scans are possible-from the beginning forward, from the end backward, 
and from the center in either direction. 
Either CALCOMP (computed controlled free-moving pen which draws figures) 
or printer (computed generated images put out on the line printer) plots are possible. 
Plots of the segment means may be obtained for both individuals and treatment 
groups. In addition, up to five individuals or treatment groups may be plotted 
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FIG. 8. An example of data analyzed and CALCOMP plotted by RSUM. Observations from two 
treatment groups have been analyzed at 4 hour intervals prior to an “event,” the occurrence of an 
LH surge on the day of estrus in sheep. Vertical bars represent one standard error limits of the 
mean of the number of observations in each time interval as shown beneath the abscissa. 
together on the same CALCOMP graph. If the individuals or groups are plotted 
separately, either CALCOMP or printer plots or both may be obtained. The 
CALCOMP plots are more involved and expensive to produce, making it advisable 
to obtain printer plots first for an approximate display of the data (Fig. 8). 
Input. The input to RSUM is summary cards which may be produced by 
RIANALS. Information on the summary card includes sample identification, time 
(year, month, day, hour, minute, or whatever portion of those numbers is appro- 
priate), treatment number (if multiple treatment groups are to be included), and the 
value together with its unitage. 
Calculations. The greater part of RSUM is concerned with setting up the frame- 
work of time segments into which data are sorted, as described in the overview. 
The calculations as such are done on two levels: by individual and by treatment 
group. Time segment means and variances may be calculated at both levels. At the 
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individual level, data values are aggregated into time segments and segment means 
and variances produced. Where multiple individuals are to be combined, the time 
segment means for such treatment groups are a weighted average-the average 
of the individuals’ means weighted by their particular variances. 
USE OF RIANAL~ FOR ASSAY QUALITY CONTROL 
It is planned to modify RIANALS to provide, on a routine basis, a single punched 
card containing selected assay quality control parameters. By comparing these 
parameters with those from previous assays of the same type (stored on previously 
punched cards), it will be possible to determine with a separate program which 
parameters are outside 95 % and 99% confidence limits as directly determined 
from analysis of all prior experiences with that assay. The results of this analysis 
can then be displayed in both summary tabular form and as batch plot scattergrams 
similar to those recommended by Rodbard et al. (5). Current experience suggests 
that useful parameters will include the assay median variance ratio, the percent 
of total labeled ligand bound in buffer control tubes and in “background” tubes, 
the slope of the standard curve, the dose of standard at the 50% intercept, and 
the assay results on two or three standard sera. 
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